Biobeat

The sensor is the product, not the model. Apply this index's standard test: remove the AI early warning score and what remains is a cleared seven parameter continuous wearable monitor with a cloud platform, which is a complete and saleable product in its own right. That is the same test that led to the iFax rejection, and Biobeat is NOT rejected on it for two reasons stated here for the record: it is healthcare specific rather than a horizontal product with a health tier, and the early warning layer does address this category's actual job rather than sitting decoratively on top. Graded C with the mechanism stated plainly. What Biobeat genuinely contributes to this category is measurement, and that contribution is real.

An automated early warning score generating real time deterioration alerts, with no published threshold, no operating characteristics, no abstention or uncertainty behaviour, and no adjunctive use statement retrieved. Users can also set their own threshold alerts on vital signs, which places some control with the institution, but nothing describes who governs the AI derived score or what a clinician is expected to do when the device based score and the hospital's existing early warning process disagree. In a category whose defining failure is alerts being ignored, a vendor adding a further automated alert stream to a ward carries a specific burden to show what its alert volume looks like, and nothing published addresses it.

A sharp split between two halves of the same product. THE SENSOR SIDE IS WELL DESCRIBED: a proprietary patented reflective photoplethysmography sensor, the derivation of seven distinct physiological parameters from that single optical signal, and clear statements of which parameters carry clearance and when each was granted. THE AI SIDE IS THE VAGUEST CLAIM IN THIS CATEGORY: the early warning score is described only as incorporating advanced AI based algorithms, with no model class, no inputs specified beyond the device's own measurements, no scoring basis, no thresholds, no validation and no statement of whether it maps to any published early warning framework such as NEWS or MEWS. This axis grades the model, and there is effectively nothing to grade. Sensor transparency is recorded as the counterweight but does not lift the grade.

The regulatory record implies measurement validation, since cuffless blood pressure derived from photoplethysmography required accuracy demonstration against reference standards to clear, and successive clearances for additional parameters imply the same each time. That is real but it is not what this axis measures well. No peer reviewed outcome study was retrieved, no named hospital deployment with published results, and critically NO VALIDATION OF THE EARLY WARNING SCORE ITSELF was located: no sensitivity, no positive predictive value, no alert burden, no lead time, and no comparison against the conventional early warning scores it implicitly competes with. For a product whose deterioration claim is the reason it belongs in this category, the deterioration claim is the least evidenced part of it.

No privacy policy, data processing statement, retention period or training use disclosure was located. Not Rated means no public evidence was found rather than evidence of weakness. The architecture makes the question sharper than usual: this is a cloud platform receiving continuous physiological telemetry from wearable devices, operated by an Israeli headquartered company selling into the US, Europe and Latin America, so processing location, cross border transfer and retention of continuous vital sign streams are all live and all unaddressed. The consumer facing capability to share data with physicians or family members adds a further consent surface that nothing published describes.

No public statement on business associate agreements, execution terms, cost or subprocessor disclosure was located. Not Rated means no public evidence was found. The cloud architecture and the absence of any named US hospital deployment mean the question is untested in public, which a US buyer should treat as something to establish early rather than assume.

No SOC 2 of any type, HITRUST, ISO 27001, trust centre or report request path was located. Not Rated means no public evidence was found. The company does hold MDSAP certification, but MDSAP IS A MEDICAL DEVICE QUALITY MANAGEMENT SYSTEM AUDIT PROGRAMME, NOT AN INFORMATION SECURITY ATTESTATION, the same distinction this index applies to ISO 13485, to CE marking and to 510(k) clearance. For a continuously transmitting cloud connected wearable estate, the absence of a published security posture is more consequential than for software running inside a hospital network.

A genuinely strong and progressively built regulatory record. Biobeat states its devices were the first ever cleared by the FDA for cuffless blood pressure monitoring derived from photoplethysmography alone, an August 2019 clearance covering continuous blood pressure, blood oxygen saturation and pulse rate. Clearance was extended in March 2022 to respiratory rate and body temperature, and again in October 2024 to stroke volume and cardiac output, giving seven cleared parameters from a single sensor. Add CE marking and MDSAP certification for international market access. Deriving haemodynamic parameters such as stroke volume and cardiac output from an optical wearable is a substantive clearance rather than a formality. THE SCOPE PRECISION MATTERS AND IS RECORDED HERE RATHER THAN LEFT IMPLICIT: these clearances cover MEASUREMENT of physiological parameters. Nothing retrieved indicates the AI based early warning score is itself cleared, so a buyer reading FDA cleared alongside AI based deterioration alerts should not conflate the two. Ask which components the clearances cover and under what regulatory basis the early warning score operates.

THE SHARPEST INSTANCE OF THE PHOTOPLETHYSMOGRAPHY PIGMENTATION PROBLEM ANYWHERE IN THIS INDEX, and it is structural rather than incidental. Pulse oximetry is well documented to overestimate arterial oxygen saturation in patients with darker skin pigmentation, a measurement bias the FDA has itself examined, and the mechanism is optical: reflective photoplethysmography measures light interaction with tissue through skin. Where this index raised the same question against Etiometry, it applied to one input among several. HERE EVERY SINGLE PARAMETER IS DERIVED FROM PPG. Blood pressure, oxygen saturation, pulse rate, respiratory rate, temperature, stroke volume and cardiac output all trace back to one optical sensor, so a pigmentation dependent measurement error does not affect one reading, it propagates through all of them and into any early warning score computed on top. Nothing published addresses this: no subgroup accuracy data by skin pigmentation, no calibration analysis, no statement of the populations in which the clearance validation was performed. PUBLISHING ACCURACY BY SKIN PIGMENTATION ACROSS THE CLEARED PARAMETERS WOULD BE THE SINGLE HIGHEST VALUE DISCLOSURE THIS VENDOR COULD MAKE, and until it exists the question should be put directly in any evaluation.

Integration into the hospital EMR is claimed and described as seamless, but no EHR vendor is named anywhere retrieved, no FHIR or SMART on FHIR capability is described, no marketplace listing or partner certification was located, and no integration architecture beyond cloud transmission is published. The interoperability position is also structurally different from the rest of this lane and worth understanding: because the device generates its own data rather than consuming existing feeds, Biobeat needs far less integration to function at all, but correspondingly it produces a parallel data stream that must be reconciled with whatever the hospital already charts, and nothing published describes how measurements flow into the record or how conflicts with cuff based readings are handled.

THE DEPLOYMENT PROPERTY IS GENUINELY DIFFERENTIATED AND IT IS THE PRACTICAL ARGUMENT FOR THIS PRODUCT. Every other vendor in this category requires integration with infrastructure the hospital already owns, whether an EHR feed, a central monitoring system or a device estate, which is precisely what excludes facilities without that infrastructure. Biobeat brings its own sensor, so a ward can be continuously monitored without a monitoring estate existing first, using a disposable patch or wrist device and a cloud platform the company describes as fast and easy to install. That materially lowers the barrier for general wards, community hospitals and hospital at home programmes. Held at B rather than A because no named hospital deployment was retrieved anywhere, no implementation timeline or scale reference exists, and no data residency commitment is published, which is a live question for cloud hosted continuous telemetry crossing borders. Named international distribution partners cover the Dominican Republic, Argentina and Chile.

No pricing published at any level: no device cost, no per patient or per patch price, no platform subscription, no band and no implementation fee. The consumable model makes this a more consequential gap than for a software only vendor, since a disposable chest patch implies recurring per patient cost that scales with monitored volume, and nothing published indicates what that is or how the wrist device is priced by comparison. One partial disclosure is noted without being credited: the company refers to a clear reimbursement pathway for ambulatory blood pressure monitoring, but no specific code or payment rate was retrieved, so this falls short of the reimbursement transparency that earned Eko and HeartSciences credit elsewhere in this index.

The widest setting span in this category, and deliberately so. Marketed coverage runs across general wards, surgical wards, post surgical recovery, step down units, medical surgical units, intensive care and emergency departments, then continues outside the hospital into ambulatory blood pressure monitoring, nursing homes and hospital at home programmes. That continuity is the product thesis rather than a list, since the same wearable follows a patient across acuity levels and out of the building, which is exactly what a discharge or step down decision needs and what no other vendor assessed here offers. Parameter coverage is also broad at seven cleared measurements from one sensor. Held at B because the cleared population is adults with no paediatric or neonatal indication retrieved, and because breadth of marketed setting is not the same as evidenced performance in each of them, none of which is published.